Biocomposites Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.biocomposites.com
Expanded Access Program (EAP) STIMULAN VG
- Conditions
- Stage IV Pressure UlcerDiabetic Foot Osteomyelitis
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Biocomposites Ltd
- Registration Number
- NCT06808568
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
Phase 2
Recruiting
- Conditions
- OsteomyelitisPressure Ulcer, Stage IV
- Interventions
- Combination Product: STIMULAN VGProcedure: Standard of Care
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Biocomposites Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06283979
- Locations
- 🇺🇸
NYU Langone Hospital - Long Island Clinical Research Center, Mineola, New York, United States
A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis
Phase 2
Recruiting
- Conditions
- Diabetic Foot Osteomyelitis
- Interventions
- Drug: STIMULAN VGDrug: Systemic Antibiotics
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Biocomposites Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05539963
- Locations
- 🇺🇸
Advanced Footcare LLC, Scottsdale, Arizona, United States
🇺🇸UNC School Medicine, Chapel Hill, North Carolina, United States
🇺🇸Titan Clinical Research, Mesa, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath